Bookbuilding for the initial public offering of KAPEKS Kimya Sanayi AŞ began on August 12, 2026. According to the company's official offering summary, orders will be accepted on August 12, 13 and 14. The shares are being offered under the KPEKS code at a fixed price of 94 Turkish lira per share. The process is led by Ziraat Yatırım Menkul Değerler AŞ and the Industrial Development Bank of Türkiye, with Yatırım Finansman Menkul Değerler AŞ acting as co-lead in the consortium.
The Capital Markets Board of Türkiye confirmed the core capital structure in its published bulletin. All 25.1 million lira in nominal shares included in the offer will come from a capital increase. The bulletin lists no sale of existing shareholder stakes and no additional share sale, while setting the price for shares with a nominal value of one lira at 94 lira.
The offering size is stated as about 2.359 billion lira and the post-offering free-float ratio as 20.06%. Those percentages describe the allocation plan, not the final number of shares any applicant will receive. Actual allocations will depend on demand and the final distribution results announced after bookbuilding closes.
According to Anadolu Agency's August 10 report, KAPEKS plans to direct proceeds toward growth investments. Public documents identify possible uses including new facilities and warehouses, automation and capacity projects at existing lines, product development, working-capital reinforcement and raw-material financing. These are management's stated intentions rather than completed investments. Their timing, cost and eventual effect will depend on later execution, so the plans should not be presented as guaranteed operating or financial outcomes.
The company and existing shareholders have also made time-limited commitments concerning new offerings and sales. Such mechanisms are disclosed parts of the transaction structure, but they do not guarantee that the market price will remain at or above the offering price.
A fixed-price bookbuilding method means the application price will not change during the three-day order period. It does not set the market price after listing. The official documents describe an equal-distribution approach for domestic individual investors, but the precise allocation can only be calculated after valid demand is known. If applications exceed the number of shares offered, some requests may not be filled in full. The eventual distribution table will therefore be a separate result from the initial timetable and allocation targets.
The documents also set out one-year commitments by the company and existing shareholders concerning actions that could increase publicly circulating shares. Readers should not treat those commitments as a standalone form of price protection. Their exact scope, exceptions and effective dates are governed by the approved prospectus and the notice to investors. Those source documents remain more authoritative than promotional summaries and should be read together with the price determination and independent audit materials.
KAP, Türkiye's public disclosure platform, carries a profile for KAPEKS under the KPEKS code. After the order period ends, final results are expected through authorized institutions and KAP. Readers assessing the offer should consult the approved prospectus, price determination report, independent audit reports and risk factors instead of relying only on brief summaries. This article reports the verified timetable and terms; it does not provide investment advice or predict a return.
The approved materials include prospectus sections, a price determination report, independent audit reports and the notice to investors. These documents explain different parts of the transaction. The completed distribution, number of applications and final results will be separate information released after bookbuilding. The announced total number of offered shares therefore does not mean every request will be filled by the same amount; final allocations will only be clear in the official results.
Because final offering results have not been announced, there is no confirmed figure for total demand or the shares allocated per applicant. This report covers only the announced terms.
